Cell Therapy Products, Total Cell Therapy Product Sales8%
Trodelvy5%
Veklury3%
Other Products, Total Other product sales3%
By geography
UNITED STATES71%
Europe17%
Other International12%
The read
Gilead Sciences, Inc. booked $29.4B in FY2025 revenue, growing 2.4% year over year — about the middle of the pack among Healthcare companies we track, at a 28.9% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.